| Abstract | Clozapine-induced neuroleptic malignant syndrome (NMS) may present differently from NMS associated with traditional antipsychotic agents, with fewer clinical features, particularly fewer extrapyramidal manifestations. The risk of developing NMS with clozapine does not appear dose-related. In half of cases, it occurs within 2 weeks of beginning clozapine therapy, but it can develop at any stage, especially with long-term use. We describe a patient who presented with atypical NMS after more than 10 years of clozapine treatment, and who was safely re-challenged with the same drug. |
| Authors | Carmela E Corallo, David Ernest
(Affiliation: Pharmacy Department, Box Hill Hospital, Box Hill, VIC.)
|
| Journal | Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
(Crit Care Resusc)
Vol. 9
Issue 4
Pg. 338-40
(Dec 2007)
ISSN: 1441-2772 Australia |
| PMID | 18052897
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antipsychotic Agents
- Clozapine
- Creatinine
|
| Topics |
- Antipsychotic Agents
(adverse effects)
- Clozapine
(adverse effects)
- Creatinine
(blood)
- Humans
- Male
- Middle Aged
- Neuroleptic Malignant Syndrome
(blood, diagnosis, etiology, physiopathology)
- Time Factors
|
